Predicting Alcoholics' Treatment Responses to a Selective Serotonin Re-uptake Inhibitor (SSRI)
Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
This study is being done to determine if citalopram is safe and effective in the treatment of
alcohol dependence. A second purpose is to evaluate whether alcohol dependent individuals who
differ in a specific genetic marker respond differently to citalopram.
Citalopram is a drug approved by the U.S. Food and Drug Administration (FDA) for the
treatment of depression. It belongs to a category of medications called selective serotonin
re-uptake inhibitors or SSRIs. The U.S. FDA has not approved citalopram for the treatment of
alcohol dependence. Therefore, it is being used "off-label" in this study.
Phase:
Phase 2
Details
Lead Sponsor:
University of Cincinnati
Collaborator:
National Institute on Alcohol Abuse and Alcoholism (NIAAA)